The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 19, 2026
Snapshot (as of Oct 19, 2026): Royalty Pharma plc (RPRX) pays a $0.91 annual dividend ($0.23 quarterly), yielding 1.54% at $60.96/share. Next ex-dividend date 2026-11-13. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 1.54%
Annual Dividend: $0.91 per share
Payout Ratio: 48.4%
Ex-Dividend Date: 2026-11-13
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 7
Royalty Pharma plc dividend income comes from an unusual source: the company buys royalties on biopharmaceutical drugs rather than developing them itself, with a portfolio spanning roughly 35 marketed therapies across oncology, rare disease, and neuroscience. RPRX currently yields 1.65%, with trailing twelve-month payments of $0.91 per share paid quarterly. The next ex-dividend date is August 14, 2026, with the most recent quarterly payment of $0.235 per share. A beta of 0.412 means RPRX stock moves far less than the broader market, which suits income investors who prioritize low volatility over high yield.
Royalty Pharma plc pays out 48.4% of earnings as dividends, a payout ratio classified as moderate (40-60%). That level leaves meaningful room between the dividend and earnings, supported by a portfolio of royalties on approximately 35 marketed therapies that generate recurring revenue without the capital intensity of drug manufacturing. Royalty Pharma plc dividend safety benefits from this royalty-based model, though the company's income depends on the commercial performance of drugs it does not control, which is the primary external pressure on the payout.
Royalty Pharma plc dividend history shows a CAGR of 6.7% per year from 2021 to 2025. The per-share annual dividend grew from $0.68 to $0.88 over that window (2026 is a partial year and excluded from the growth calculation). The smallest annual increase in the window was 4.8% in 2025, down from a peak of 11.8% in 2022. Growth is slowing, and at the current pace, income investors should expect mid-single-digit raises rather than double-digit bumps going forward.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +5.0% | $0.76 (2022) | $0.88 (2025) |
| 5-Year | +24.0% | $0.30 (2020) | $0.88 (2025) |
RPRX fits dividend investors who want low market sensitivity and steady, if unspectacular, income growth. The yield is low (below 2%) and currently sits below the 5-year average of 2.17%, meaning buyers today are accepting less income than the stock has historically offered. The 48.4% payout ratio keeps the dividend well-covered, and four consecutive years of increases show a commitment to growing the payment. The trade-off is straightforward: Royalty Pharma plc stock offers a cushioned ride with a growing but modest yield, not a high-income payout.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-14 | $0.2350 |
| 2026-05-15 | $0.2350 |
| 2026-02-20 | $0.2350 |
| 2025-11-14 | $0.2200 |
| 2025-08-15 | $0.2200 |
| 2025-05-16 | $0.2200 |
| 2025-02-21 | $0.2200 |
| 2024-11-15 | $0.2100 |
| 2024-08-16 | $0.2100 |
| 2024-05-16 | $0.2100 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.7050 |
| 2025 | $0.8800 |
| 2024 | $0.8400 |
| 2023 | $0.8000 |
| 2022 | $0.7600 |
Project income from RPRX with the RPRX dividend calculator or track your full portfolio with the dividend tracker.